I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EURETINA 2022

-
Coming soon
10:30 AM
Duration 4mins Virtual
Anti–vascular endothelial growth factor treatment intervals and visual outcomes in patients with diabetic macular edema: analysis from 4 National Health Service centres in the United Kingdom
Ghanchi F, Peto T, Talks S J, Chuo J, Ferrara D, Spicer,G Balasubramanian S, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Characterising Anti–Vascular Endothelial Growth Factor (VEGF) Treatment Patterns for Neovascular Age-Related Macular Degeneration in the United Kingdom
Fenech M, Jain M, Cantrell R, Chidambaram J, Judge D, Dodds M, McGrory S, Bailey C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Clinical Trial Versus Real-world Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion
Baumal C, Danzig C, Blotner S, Steffen V, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
4mins Virtual
Faricimab in neovascular age-related macular degeneration (nAMD): efficacy, safety, and durability through week 48 in the phase 3 TENAYA and LUCERNE trials
Cheung CMG, Guymer R, Demetriades AM, Margaron P, Quezada Ruiz C, Silverman D, Ives J, Basu K, Souverain A, Yang M, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins Virtual
Long-term Safety and Efficacy of the Port Delivery System With Ranibizumab in Neovascular Age-Related Macular Degeneration: Interim Analysis of the Portal Extension Trial
Eter N, Eichenbaum D, Callaway N, Morral M, Smith R, Campochiaro P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:02 AM
Duration 6mins Congress Center Hamburg, Germany
Patient Experience with Anti-VEGF Intravitreal Injections in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema: A Multinational Observational Study
Giocanti A, Holekamp N, Sheeth V, Peto T, Kertes P, Layana AG, Viola F, Barbier V, Lewis H, Lambert J, Gentile B, Chi G, Mirt M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:14 AM
Duration 6mins Congress Center Hamburg, Germany
End-of-Study Retinal Fluid and Vision Outcomes in the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Rachitskaya A, Blotner S, Heinrich D, Gune S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:32 AM
Duration 6mins Congress Center Hamburg, Germany
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
Figueroa M, Pearce I, Demetriades AM, Kotecha A, Silverman D, Swaminathan B, Patel V, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 6mins Congress Center Hamburg, Germany
Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Interval Cohort in the Phase 3 TENAYA and LUCERNE Trials
Lai T, Michels S, Demetriades AM, Quezada Ruiz C, Silverman D, Ives J, Swaminathan B, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:23 PM
Duration 6mins Congress Center Hamburg, Germany
Personalised Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Korobelnik JF, Jaffe GJ, Gerendas BS, Abreu F, Camino A, Jain N, Tang Y, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:29 PM
Duration 6mins Congress Center Hamburg, Germany
Angiopoietin-2 signalling and vascular stability with faricimab in diabetic macular edema
Joussen A, Willis JR, Haskova Z, Westenskow PD, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:35 PM
Duration 6mins Congress Center Hamburg, Germany
Predicting 5-year progression to vision-threatening complications using machine learning
Cunha-Vaz J, Dampolous D, Mendes L, Santos T, Neubert A, Ferrara D, Benmansour F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:53 PM
Duration 6mins Congress Center Hamburg, Germany
VOYAGER: An Innovative, Global, Observational Study to Gain Real-world Insights Into the Long-term Utilisation of the Port Delivery System With Ranibizumab and Faricimab for the Treatment of nAMD and DME
Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger R, Gallego R, Koh A, Lövestam M, Parravano M, Luna Pinto JD, Schmitz-Valckenberg MS, Sheth V, Souied E, Chi G, Glittenberg C, Scheidl S, Bengus M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:05 PM
Duration 6mins Congress Center Hamburg, Germany
Deep Learning Model to Identify Moderately Severe and Severe Non-proliferative Diabetic Retinopathy From 7-Field Colour Fundus Photographs
Cunha-Vaz J, Dampoloulos D, Yang Q, Neubert A, Mendes L, Santos T, Sredar N, Ferrara D, Benmansour F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:23 PM
Duration 6mins Congress Center Hamburg, Germany
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Holz F, Khanani A, Demetriades A-M, Kotecha A, Silverman D, Swaminathan B, Patel V, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:45 PM
Duration 5mins Hamburg, Germany / Virtual (Hybrid)
View the EURETINA 2022 symposium on Advancing the management of nAMD: Latest clinical insights from targeting Ang-2/VEGF-A via dual inhibition
Holz F, Cheung G, Tadayoni R and Khanani AM

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:29 PM
Duration 6mins Congress Center Hamburg, Germany
Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
Figueroa M, Holekamp N, Bobbala A, Callaway N, DeGraaf S, Menezes A, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:35 PM
Duration 6mins Congress Center Hamburg, Germany
Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the Port Delivery System With Ranibizumab (PDS)
Chakravarthy U, Blotner S, Heinrich D, Gune S, Sheth V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:41 PM
Duration 6mins Congress Center Hamburg, Germany
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab
Khanani A, Singh N, Barteselli G, Callaway N, Patel S, Jaycock P, Menezes A, Malhotra V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:27 PM
Duration 6mins Congress Center Hamburg, Germany
Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Schlottmann PG, Wells JA, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:32 PM
Duration 6mins Congress Center Hamburg, Germany
HONU: A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Guymer R, Wu Z, Datta S, Steffen V, Gao S, Zhang M, Litts KM, Chang MC, Elstrott J, Zhang J, Liu L, Willis J, Chen H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:08 PM
Duration 6mins Congress Center Hamburg, Germany
Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration: End-of-Study Results
Rizzo S, Brooks L, Mittra R, Wykoff C, Callaway N, DeGraaf S, Fung AE, Gune S, LePogam S, Smith R, Willis J, Barteselli G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:14 PM
Duration 6mins Congress Center Hamburg, Germany
Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
Becker M, Sheth V, Callaway N, Malhotra V, Menezes A, Singh N, Jaycock P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:45 PM
Duration 5mins Hamburg, Germany / Virtual (Hybrid)
View the EURETINA 2022 symposium on Expert clinical insights: How continuous delivery of anti-VEGF is changing the management of nAMD
Wolf A, Figueroa MS and Khanani AM

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:45 PM
Duration 5mins Hamburg, Germany / Virtual (Hybrid)
View the EURETINA 2022 symposium on Broadening management options for DME: Recent clinical insights from targeting dual inhibition of Ang-2 and VEGF-A
Korobelnik J-F, Wong TY, Westenskow P, and Holekamp N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:12 PM
Duration 5mins Congress Center Hamburg, Germany
Quantification of Lesion Progression of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration
Schmitz-Valckenberg S, Sassmannshausen M, Braun M, Steffen V, Gao S, Honigberg L, Ferrara D, Pfau M, Holz

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar